Scala Christopher, Oesterwind Melanie, Lanot Thomas
Marineland, 06600 Antibes, France.
Laboratoire de Pharmacocinétique et Toxicologie, Institut Fédératif de Biologie, Centre Hospitalier Universitaire Purpan, 31400 Toulouse, France.
J Avian Med Surg. 2023 Mar;36(4):400-405. doi: 10.1647/21-00054.
Avian malaria is an important cause of mortality in captive penguins housed in outdoor exhibits. Mefloquine was used as a prophylaxis to treat a colony of 19 Humboldt penguins () for avian malaria. A target dose of 30 mg/kg was obtained from anecdotal literature for sphenisciforms that was not based on pharmacokinetic or toxicity studies. For this reason, preliminary plasma concentrations of mefloquine were acquired after the first dose in some penguins to ensure that plasma concentrations reached human malaria prophylactic concentrations. Afterward, each penguin in the entire colony received mefloquine (26-31 mg/kg [125 mg in toto] PO q7d). Regurgitation was frequently observed starting after the fourth weekly administration. Plasma concentrations of mefloquine after the seventh dose showed elevated concentrations, and the treatment was immediately terminated. Eight penguins died during and after the treatment period. The first fatality occurred after the fifth weekly administration, and 7 birds died within 7-52 days after the seventh weekly administration. Three penguins were found dead without previous symptoms. The other five presented with marked lethargy, dyspnea, poor appetite, and vomiting, and all died despite medical care. The remaining 11 penguins of the colony survived without any supportive care; 5 did not exhibit any clinical disease signs, while the other 6 showed a mild apathy and decreased appetite. Mefloquine toxicity was highly suspected on the basis of clinical signs, the elevated mefloquine plasma concentrations, and no other underlying pathologic disease conditions identified through postmortem examinations. Nonspecific lesions, including pulmonary congestion and edema and hepatic perivascular hematopoiesis, were noted in the birds that died. Additionally, 1 case presented with myocarditis, and mycobacteria were observed within granulomas in the respiratory tract of 2 penguins. Caution is advised, and further studies are encouraged before administering mefloquine to penguins.
禽疟是户外展区圈养企鹅死亡的一个重要原因。甲氟喹被用作预防药物,用于治疗一群19只洪堡企鹅的禽疟。从非基于药代动力学或毒性研究的关于企鹅目的文献中获得了30mg/kg的目标剂量。因此,在一些企鹅首次给药后获取了甲氟喹的初步血浆浓度,以确保血浆浓度达到人类疟疾预防浓度。此后,整个企鹅群体中的每只企鹅都接受了甲氟喹(26 - 31mg/kg[总量125mg]口服,每7天一次)。从第四次每周给药后开始,经常观察到反刍现象。第七次给药后的甲氟喹血浆浓度显示升高,治疗立即终止。在治疗期间及之后有8只企鹅死亡。首例死亡发生在第五次每周给药后,7只企鹅在第七次每周给药后7 - 52天内死亡。3只企鹅在没有先前症状的情况下被发现死亡。另外5只表现出明显嗜睡、呼吸困难、食欲不振和呕吐,尽管接受了医疗护理但全部死亡。该群体中其余11只企鹅在没有任何支持性护理的情况下存活下来;5只没有表现出任何临床疾病体征,而另外6只表现出轻度冷漠和食欲下降。基于临床症状、甲氟喹血浆浓度升高以及死后检查未发现其他潜在病理疾病状况,高度怀疑是甲氟喹中毒。在死亡的企鹅中发现了非特异性病变,包括肺充血、水肿和肝血管周围造血。此外,1例出现心肌炎,在2只企鹅呼吸道的肉芽肿内观察到分枝杆菌。建议谨慎行事,并鼓励在给企鹅使用甲氟喹之前进行进一步研究。